bintrafusp alfa + cisplatin

**Bintrafusp alfa + cisplatin** is an investigational combination therapy consisting of bintrafusp alfa—a recombinant bifunctional fusion protein that targets two key immunosuppressive pathways—and cisplatin, a platinum-based chemotherapeutic. Bintrafusp alfa functions by simultaneously blocking transforming growth factor beta (TGF-β) via receptor "trap" and programmed death-ligand 1 (PD-L1) via monoclonal antibody blockade, designed to enhance antitumor immune responses. Cisplatin crosslinks DNA, leading to apoptosis in cancer cells. This combination has been studied in the treatment of advanced biliary tract cancer and locally advanced, persistent, recurrent, or metastatic cervical cancer, primarily in first-line settings. The drug combination is under development by Merck KGaA (bintrafusp alfa) and is used in combination with standard platinum-based chemotherapy regimens[1][3].